Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactions-reply

被引：0
|
作者：
Giada Crescioli
Cecilia Lanzi
Guido Mannaioni
Alfredo Vannacci
Niccolò Lombardi
机构：
[1] University of Florence,Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology
[2] Tuscan Regional Centre of Pharmacovigilance,Toxicology Unit and Poison Centre
[3] Careggi University Hospital,undefined
来源：
Internal and Emergency Medicine | 2021年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：799 / 800
页数：1
相关论文
共 50 条
  • [31] The advantages of drug treatment with statins in patients with SARS-CoV-2 infection
    Francesco Ferrara
    Antonio Vitiello
    Wiener klinische Wochenschrift, 2021, 133 : 958 - 965
  • [32] The advantages of drug treatment with statins in patients with SARS-CoV-2 infection
    Ferrara, Francesco
    Vitiello, Antonio
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (17-18) : 958 - 965
  • [33] Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
    Grygiel-Gorniak, Bogna
    Shaikh, Osama
    Kumar, Nikita Niranjan
    Hsu, Shao Heng
    Samborski, Wlodzimierz
    REUMATOLOGIA, 2021, 59 (04): : 252 - 259
  • [34] DRUG INTERACTIONS AND ADVERSE DRUG REACTIONS IN THE OLDER PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT
    De Paepe, P.
    Petrovic, M.
    Outtier, L.
    Van Maele, G.
    Buylaert, W.
    ACTA CLINICA BELGICA, 2013, 68 (01): : 15 - 21
  • [35] Potential of drug interactions as a cause of adverse drug reactions in patients with kidney diseases
    Shahraki, Tahereh Gholipur
    Yari, Fatemeh
    Seirafian, Shiva
    Badri, Shirinsadat
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (02) : 121 - 124
  • [36] Renal function underestimated in elderly hospitalised patients with adverse drug reactions
    Helldén, A
    Johansson, M
    Öhlén, G
    Bergman, U
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (11) : A221 - A221
  • [37] The SARS-CoV-2 main protease as drug target
    Ullrich, Sven
    Nitsche, Christoph
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (17)
  • [38] A community effort in SARS-CoV-2 drug discovery
    Schimunek, Johannes
    Seidl, Philipp
    Elez, Katarina
    Hempel, Tim
    Le, Tuan
    Noe, Frank
    Olsson, Simon
    Raich, Lluis
    Winter, Robin
    Gokcan, Hatice
    Gusev, Filipp
    Gutkin, Evgeny M.
    Isayev, Olexandr
    Kurnikova, Maria G.
    Narangoda, Chamali H.
    Zubatyuk, Roman
    Bosko, Ivan P.
    Furs, Konstantin V.
    Karpenko, Anna D.
    Kornoushenko, Yury V.
    Shuldau, Mikita
    Yushkevich, Artsemi
    Benabderrahmane, Mohammed B.
    Bousquet-Melou, Patrick
    Bureau, Ronan
    Charton, Beatrice
    Cirou, Bertrand C.
    Gil, Gerard
    Allen, William J.
    Sirimulla, Suman
    Watowich, Stanley
    Antonopoulos, Nick A.
    Epitropakis, Nikolaos E.
    Krasoulis, Agamemnon K.
    Pitsikalis, Vassilis P.
    Theodorakis, Stavros T.
    Kozlovskii, Igor
    Maliutin, Anton
    Medvedev, Alexander
    Popov, Petr
    Zaretckii, Mark
    Eghbal-Zadeh, Hamid
    Halmich, Christina
    Hochreiter, Sepp
    Mayr, Andreas
    Ruch, Peter
    Widrich, Michael
    Berenger, Francois
    Kumar, Ashutosh
    Yamanishi, Yoshihiro
    MOLECULAR INFORMATICS, 2024, 43 (01)
  • [39] Drug Weaponry to Fight Against SARS-CoV-2
    Cabezon, Elena
    Arechaga, Ignacio
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [40] Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
    Patocka, Jiri
    Kuca, Kamil
    Oleksak, Patrik
    Nepovimova, Eugenie
    Valis, Martin
    Novotny, Michal
    Klimova, Blanka
    PHARMACEUTICALS, 2021, 14 (03)
12345